| . "Bayesian inference for network meta-regression using multivariate random effects with applications to cholesterol lowering drugs.." Biostatistics. 2019;20(3):499-516. Pub Med |
| . "Meta-analysis methods and models with applications in evaluation of cholesterol-lowering drugs.." Stat Med. 2012;31(28):3597-616. Pub Med |
| . "Bayesian multivariate skew meta-regression models for individual patient data.." Stat Methods Med Res. 2019;28(10-11):3415-3436. Pub Med |
| . "Inference for optimal dynamic treatment regimes using an adaptive m-out-of-n bootstrap scheme.." Biometrics. 2013;69(3):714-23. Pub Med |
| . "A global logrank test for adaptive treatment strategies based on observational studies.." Stat Med. 2014;33(5):760-71. Pub Med |
| . "A penalized likelihood approach for investigating gene-drug interactions in pharmacogenetic studies.." Biometrics. 2015;71(2):529-37. Pub Med |
| . "Reinforcement learning strategies for clinical trials in nonsmall cell lung cancer.." Biometrics. 2011;67(4):1422-33. Pub Med |
| . "Accelerated intensity frailty model for recurrent events data.." Biometrics. 2014;70(3):579-87. Pub Med |
| . "Prediction of cancer drug sensitivity using high-dimensional omic features.." Biostatistics. 2017;18(1):1-14. Pub Med |
| . "Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.." Future Oncol. 2016;12(11):1359-67. Pub Med |
| . "Dose-finding designs for trials of molecularly targeted agents and immunotherapies.." J Biopharm Stat. 2017;27(3):477-494. Pub Med |
| . "Enrollment and stopping rules for managing toxicity requiring long follow-up in phase II oncology trials.." J Biopharm Stat. 2015;25(6):1206-14. Pub Med |
| . "Nine-year change in statistical design, profile, and success rates of Phase II oncology trials.." J Biopharm Stat. 2016;26(1):141-9. Pub Med |
| . "Biomarker threshold adaptive designs for survival endpoints.." J Biopharm Stat. 2018;28(6):1038-1054. Pub Med |
| . "Clinical trials data collection: When less is more.." J Clin Oncol. 2010;28(34):5019-21. Pub Med |
| . "Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology.." J Pharmacol Exp Ther. 2013;347(3):599-606. Pub Med |
| . "Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.." Lancet Oncol. 2017;18(6):732-742. Pub Med |
| . "Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs.." Nat Commun. 2019;10(1):309. Pub Med |
| . "Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity.." Pharmacogenomics. 2013;14(2):205-13. Pub Med |
| . "Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.." Pharmacogenomics. 2013;14(5):555-74. Pub Med |
| . "Cancer pharmacogenomics: early promise, but concerted effort needed.." Science. 2013;339(6127):1563-6. Pub Med |
| . "Sample size and power determination in joint modeling of longitudinal and survival data.." Stat Med. 2011;30(18):2295-309. Pub Med |
| . "Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint.." Stat Med. 2011;30(13):1502-18. Pub Med |
| . "Assessing model fit in joint models of longitudinal and survival data with applications to cancer clinical trials.." Stat Med. 2014;33(27):4715-33. Pub Med |
| . "Biomarker threshold adaptive designs for survival endpoints.." J Biopharm Stat. 2018;28(6):1038-1054. Pub Med |
| . "Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy.." Nat Commun. 2020;11(1):6410. Pub Med |
| . "A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101.." Clin Cancer Res. 2012;18(18):5099-109. Pub Med |
| . "Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia.." Ann Oncol. 2019;30(4):542-550. Pub Med |
| . "Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR(+), HER2(-) breast cancer that had progressed during or after prior endocrine therapy.." Breast Cancer Res. 2017;19(1):18. Pub Med |
| . "Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer.." Breast Cancer Res Treat. 2017;166(1):167-177. Pub Med |
| . "Predictive blood-based biomarkers in patients with epithelial ovarian cancer treated with carboplatin and paclitaxel with or without bevacizumab: Results from GOG-0218.." Clin Cancer Res. 2020;26(6):1288-1296. Pub Med |
| . "Practical designs for Phase I combination studies in oncology.." J Biopharm Stat. 2016;26(1):150-66. Pub Med |
| . "Celecoxib with neoadjuvant chemotherapy for breast cancer might worsen outcomes differentially by COX-2 expression and ER status: Exploratory analysis of the REMAGUS02 trial.." J Clin Oncol. 2019;37(8):624-635. Pub Med |
| . "Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.." J Natl Cancer Inst. 2012;104(3):211-27. Pub Med |
| . "Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.." Lancet Oncol. 2017;18(6):732-742. Pub Med |
| . "Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer.." Lung Cancer. 2020;141():14-20. Pub Med |
| . "Pattern mixture models for clinical validation of biomarkers in the presence of missing data.." Stat Med. 2017;36(19):2994-3004. Pub Med |
| . "Set-valued dynamic treatment regimes for competing outcomes.." Biometrics. 2014;70(1):53-61. Pub Med |
| . "Incorporating patient preferences into estimation of optimal individualized treatment rules.." Biometrics. 2018;74(1):18-26. Pub Med |
| . "Inference on phenotype-specific effects of genes using multivariate kernel machine regression.." Genet Epidemiol. 2018;42(1):64-79. Pub Med |
| . "Multivariate phenotype association analysis by marker-set kernel machine regression.." Genet Epidemiol. 2012;36(7):686-95. Pub Med |
| . "Localized differences in caudate and hippocampal shape are associated with schizophrenia but not antipsychotic type.." Psychiatry Res. 2013;211(1):1-10. Pub Med |
| . "Comparison of adaptive treatment strategies based on longitudinal outcomes in sequential multiple assignment randomized trials.." Stat Med. 2017;36(3):403-415. Pub Med |
| . "A multiple imputation strategy for sequential multiple assignment randomized trials.." Stat Med. 2014;33(24):4202-14. Pub Med |
| . "Mixed model analysis of censored longitudinal data with flexible random-effects density.." Biostatistics. 2012;13(1):61-73. Pub Med |
| . "Predicting Alzheimer's disease using combined imaging-whole genome SNP data.." J Alzheimers Dis. 2015;46(3):695-702. Pub Med |
| . "Analysis of secondary phenotypes in multigroup association studies.." Biometrics. 2020;76(2):606-618. Pub Med |
| . "PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.." Sci Transl Med. 2016;8(369):369ra175. Pub Med |
| . "Time-dependent classification accuracy curve under marker-dependent sampling.." Biom J. 2016;58(4):974-92. Pub Med |
| . "Multicategory reclassification statistics for assessing improvements in diagnostic accuracy.." Biostatistics. 2013;14(2):382-94. Pub Med |
